# A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets

> **NCT04275050** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor

## Interventions

- **DRUG:** TQB3303

## Key facts

- **NCT ID:** NCT04275050
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04
- **Primary completion:** 2021-04
- **Final completion:** 2022-04
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04275050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04275050, "A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04275050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*